Who is sponsoring NCT01768338?

NCT01768338 is sponsored by Michael John Robertson.

What condition does NCT01768338 study?

NCT01768338 studies Non-Hodgkin's Lymphoma.

What drugs are being tested in NCT01768338?

Interventions: Ofatumumab combined with SB-485232.

What is the status of NCT01768338?

NCT01768338 is currently COMPLETED.

Last reviewed 2023-02-08 · How we verify

A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

NCT01768338 Phase 1 COMPLETED

The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.

Details

Lead sponsor	Michael John Robertson
Phase	Phase 1
Status	COMPLETED
Enrolment	9
Start date	2013-02
Completion	2017-08-03

Conditions

Non-Hodgkin's Lymphoma

Interventions

Ofatumumab combined with SB-485232

Primary outcomes

To evaluate the the number of subjects with adverse events who receive SB-485232 when given in combination with ofatumumab — 8 weeks
Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 which uses a scale of 1 (mild) to 5 (caused death).

Countries

United States